CFD 属于复杂的高风险金融工具,其杠杆作用可能导致投资者迅速亏损。 84% 的散户投资者因进行 CFD 交易遭受资金损失。 请您谨慎考虑自己是否了解 CFD 操作,以及是否能够接受高额亏损的风险。

Scan to Download iOS&Android APP

交易 Inozyme Pharma, Inc. - INZY CFD

-
0%
  • 概括
  • 历史数据
  • 活动
  • 收入报表
  • 资产负债表
  • 现金流
  • 所有权
交易条件
价差 -
多头隔夜费

Long position overnight fee


Margin. Your investment $1,000.00
隔夜费用 -0.030779 %
Charges from borrowed part ($-1.23)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

前往平台
-0.030779%
空头隔夜费

Short position overnight fee


Margin. Your investment $1,000.00
隔夜费用 -0.013666 %
Charges from borrowed part ($-0.55)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

前往平台
-0.013666%
隔夜费时间 22:00 (UTC)
最小交易量 1
货币 USD
保证金 20%
上市交易所 United States of America
交易费 0%

*Information provided by Capital.com

关键数据
前收盘价* N/A
开盘价* N/A
1 年变化* N/A
日范围* N/A
52 周范围 0.99-7.98
平均交易量(10 天) 356.67K
平均交易量(3 个月) 4.06M
市值 99.77M
市盈率 -100.00K
流通股 40.39M
收入 N/A
EPS -2.26
股息(收益率 %) N/A
贝塔 -100.00K
下一个财报发布日期 Mar 13, 2023

所有数据都是由Refinitiv提供的, 除了标有星号的数据, 这是*由 Capital.com 提供的数据

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date 平倉 Change Change (%) 開倉 High Low

Inozyme Pharma, Inc. Events

Time (UTC) Country Event
No events scheduled
View all events
  • 年度
  • 每季度
2018 2019 2020 2021
总收入 0 0 0 0
总营业费用 11.593 20.806 57.041 56.646
销售/一般/行政费用,总计 3.494 4.586 10.548 18.926
研究与开发 8.099 16.22 46.493 37.72
营业收入 -11.593 -20.806 -57.041 -56.646
利息收入(费用),非经营净值 0.284 1.106 0.37 0.211
其他,净值 4.345 -0.024 0.247 -0.189
税前净收入 -6.964 -19.724 -56.424 -56.624
税后净收入 -6.964 -19.724 -56.424 -56.624
未计算非常项目前的净收益 -6.964 -19.724 -56.424 -56.624
净收入 -6.964 -19.724 -56.424 -56.624
普通股股东可获收益 (不含非经常性项目) -6.964 -19.724 -56.424 -56.624
普通股股东可获收益 (含非經常性項目) -6.964 -19.724 -56.424 -56.624
摊薄净收入 -6.964 -19.724 -56.424 -56.624
摊薄后加权平均股 20.3148 20.3148 11.0365 23.5583
扣除特别项目的每股摊薄盈利 -0.3428 -0.97092 -5.11249 -2.40357
Dividends per Share - Common Stock Primary Issue 0 0
每股正常摊薄盈利 -0.3428 -0.97092 -5.11249 -2.40357
Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022
总收入 0 0 0 0 0
总营业费用 10.972 12.655 14.262 18.757 16.839
销售/一般/行政费用,总计 4.369 4.435 4.916 5.206 5.025
研究与开发 6.603 8.22 9.346 13.551 11.814
营业收入 -10.972 -12.655 -14.262 -18.757 -16.839
利息收入(费用),非经营净值 0.063 0.058 0.047 0.043 0.06
其他,净值 -0.141 0.057 -0.065 -0.04 -0.105
税前净收入 -11.05 -12.54 -14.28 -18.754 -16.884
税后净收入 -11.05 -12.54 -14.28 -18.754 -16.884
未计算非常项目前的净收益 -11.05 -12.54 -14.28 -18.754 -16.884
净收入 -11.05 -12.54 -14.28 -18.754 -16.884
普通股股东可获收益 (不含非经常性项目) -11.05 -12.54 -14.28 -18.754 -16.884
普通股股东可获收益 (含非經常性項目) -11.05 -12.54 -14.28 -18.754 -16.884
摊薄净收入 -11.05 -12.54 -14.28 -18.754 -16.884
摊薄后加权平均股 23.4295 23.4906 23.6435 23.6673 23.6863
扣除特别项目的每股摊薄盈利 -0.47163 -0.53383 -0.60397 -0.7924 -0.71282
Dividends per Share - Common Stock Primary Issue 0 0 0 0
每股正常摊薄盈利 -0.47163 -0.53383 -0.60397 -0.7924 -0.71282
  • 年度
  • 每季度
2018 2019 2020 2021
流动资产总额 43.267 47.46 150.979 115.342
现金和短期投资 43.163 47.132 147.697 111.801
现金等价物 35.966 31.605 28.04 23.316
短期投资 7.197 15.527 119.657 88.485
应收账款总额,净额 0.031 0.104 0.155 0.062
Prepaid Expenses 0.073 0.224 3.127 3.479
Total Assets 43.543 47.944 169.363 123.541
Property/Plant/Equipment, Total - Net 0.242 0.298 2.648 4.436
Property/Plant/Equipment, Total - Gross 0.269 0.408 2.975 5.437
Accumulated Depreciation, Total -0.027 -0.11 -0.327 -1.001
Other Long Term Assets, Total 0.034 0.186 3.537 3.763
Total Current Liabilities 2.389 3.236 9.973 11.633
Accounts Payable 0.984 0.901 3.069 2.394
Accrued Expenses 1.405 2.335 6.625 9.239
Notes Payable/Short Term Debt 0 0 0 0
Total Liabilities 2.389 3.236 11.26 14.273
Total Long Term Debt 0 0 0 0
Total Equity 41.154 44.708 158.103 109.268
Preferred Stock - Non Redeemable, Net 55.029 77.927
Common Stock 0.001 0.001 0.002 0.002
Additional Paid-In Capital 1.054 1.427 249.175 256.948
Retained Earnings (Accumulated Deficit) -14.928 -34.652 -91.076 -147.7
Other Equity, Total -0.002 0.005 0.002 0.018
Total Liabilities & Shareholders’ Equity 43.543 47.944 169.363 123.541
Total Common Shares Outstanding 20.3148 20.3148 23.385 23.6726
Total Preferred Shares Outstanding 72.4164
Long Term Investments 12.199 0
Other Current Liabilities, Total 0.279 0
Other Liabilities, Total 1.287 2.64
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
流动资产总额 148.041 140.962 130.579 115.342 100.583
现金和短期投资 145.086 137.464 125.283 111.801 97.773
现金等价物 16.486 26.239 27.229 23.316 31.943
短期投资 128.6 111.225 98.054 88.485 65.83
应收账款总额,净额 0.122 0.095 0.073 0.062 0.048
Prepaid Expenses 2.833 3.403 5.223 3.479 2.762
Total Assets 158.915 148.259 137.746 123.541 108.931
Property/Plant/Equipment, Total - Net 5.029 4.859 4.743 4.436 4.184
Property/Plant/Equipment, Total - Gross 5.514 5.511 5.562 5.437 5.363
Accumulated Depreciation, Total -0.485 -0.652 -0.819 -1.001 -1.179
Long Term Investments 2.548 0 0 0
Other Long Term Assets, Total 3.297 2.438 2.424 3.763 4.164
Total Current Liabilities 6.832 6.972 8.943 11.633 12.26
Accounts Payable 1.709 0.796 0.626 2.394 2.2
Accrued Expenses 5.123 6.176 8.317 9.239 10.06
Notes Payable/Short Term Debt 0 0 0 0 0
Total Liabilities 10.026 9.985 11.772 14.273 14.702
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 3.194 3.013 2.829 2.64 2.442
Total Equity 148.889 138.274 125.974 109.268 94.229
Common Stock 0.002 0.002 0.002 0.002 0.002
Additional Paid-In Capital 251.001 252.92 254.915 256.948 258.94
Retained Earnings (Accumulated Deficit) -102.126 -114.666 -128.946 -147.7 -164.584
Other Equity, Total 0.012 0.018 0.003 0.018 -0.129
Total Liabilities & Shareholders’ Equity 158.915 148.259 137.746 123.541 108.931
Total Common Shares Outstanding 23.4737 23.5706 23.6647 23.6726 23.8184
Other Current Liabilities, Total 0 0 0
Preferred Stock - Non Redeemable, Net 0 0
  • 年度
  • 每季度
2018 2019 2020 2021
净收入/起跑线 -6.964 -19.724 -56.424 -56.624
经营活动产生的现金 -9.437 -18.81 -35.974 -48.153
经营活动产生的现金 0.026 0.083 0.217 0.674
非现金物品 -3.93 0.23 20.344 7.712
营运资金的变化 1.431 0.601 -0.111 0.085
投资活动产生的现金 9.006 -8.391 -117.179 42.796
资本支出 -0.259 -0.139 -0.568 -0.397
其他投资现金流量项目,总计 9.265 -8.252 -116.611 43.193
融资活动产生的现金 31.945 22.97 149.812 0.609
股票的发行(报废),净额 31.945 22.97 149.812 0.609
现金净变化 31.514 -4.231 -3.341 -4.724
外汇效应 0.024
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Net income/Starting Line -11.05 -23.59 -37.87 -56.624 -16.884
Cash From Operating Activities -12.376 -22.409 -34.709 -48.153 -14.16
Cash From Operating Activities 0.158 0.325 0.492 0.674 0.178
Non-Cash Items 1.725 3.689 5.567 7.712 1.779
Changes in Working Capital -3.209 -2.833 -2.898 0.085 0.767
Cash From Investing Activities 0.573 20.247 33.309 42.796 22.562
Capital Expenditures -0.088 -0.278 -0.357 -0.397 -0.017
Other Investing Cash Flow Items, Total 0.661 20.525 33.666 43.193 22.579
Cash From Financing Activities 0.249 0.361 0.598 0.609 0.24
Issuance (Retirement) of Stock, Net 0.249 0.361 0.598 0.609 0.24
Net Change in Cash -11.554 -1.801 -0.811 -4.724 8.627
Foreign Exchange Effects -0.009 0.024 -0.015
投资者名称 投资者类型 流通股百分比 持有股份 股份变动 持有日期 换手率
Longitude Capital Management Co., LLC Venture Capital 10.3341 4174379 1355000 2022-04-19 LOW
Sofinnova Investments, Inc Venture Capital 9.0491 3655308 0 2022-09-30 MED
Deep Track Capital LP Hedge Fund 8.0457 3250000 0 2022-09-30 MED
Rock Springs Capital Management LP Hedge Fund 6.9505 2807618 167562 2022-09-30 LOW
VR Adviser, LLC Venture Capital 6.7088 2709987 0 2022-09-30 LOW
Pivotal Bioventure Partners Investment Advisor LLC Investment Advisor 6.5879 2661154 0 2022-09-30 LOW
Adage Capital Management, L.P. Hedge Fund 6.4283 2596672 50000 2022-09-30 LOW
New Enterprise Associates (NEA) Venture Capital 6.0513 2444379 0 2022-09-30 LOW
Deerfield Management Company, L.P. Hedge Fund 5.1751 2090436 -605936 2022-09-30 MED
Cowen Investment Management LLC Investment Advisor/Hedge Fund 4.942 1996277 -37525 2022-09-30 MED
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 3.3249 1343063 -11153 2022-09-30 LOW
Sphera Funds Management Ltd. Hedge Fund 2.909 1175058 9458 2022-09-30 MED
Janus Henderson Investors Investment Advisor/Hedge Fund 1.7467 705577 -224379 2022-09-30 LOW
BioImpact Capital LLC Investment Advisor/Hedge Fund 1.6367 661144 -3836 2022-09-30 LOW
Fidelity Management & Research Company LLC Investment Advisor 1.5086 609380 -439 2022-09-30 LOW
Laurion Capital Management LP Hedge Fund 0.6729 271800 0 2022-09-30 HIGH
Bolte (Axel) Individual Investor 0.6483 261890 3315 2022-09-30 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 0.6395 258321 -1011 2022-09-30 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.5785 233685 16760 2022-09-30 LOW
Jungles (Steven J) Individual Investor 0.4982 201262 159226 2022-04-19

为什么选择 Capital.com?让我们的数字来说话。

Capital.com Group
+485000+

交易者

65000+

每月活跃客户

$48000000+

每月投资额

$28000000+

每月提取金额

交易計算器

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

貿易佣金
0
  • 1:1
  • 2:1
  • 5:1
  • 10:1
  • 20:1
杠杆
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
投資
交易規模(槓桿 x 投資):
開倉

平倉

做空 做多

Inozyme Pharma, Inc. Company profile

关于 Inozyme Pharma Inc.

Inozyme Pharma, Inc.是一家处于临床阶段的罕见疾病生物制药公司。 该公司专注于开发治疗影响血管、软组织和骨骼的异常矿化疾病的疗法。 该公司还专注于开发一种治疗罕见遗传病的疗法,即八核苷酸焦磷酸酶/磷酸二酯酶1(ENPP1)和ATP结合盒亚家族C成员6(ABCC6)的缺陷。 公司的主要候选产品INZ-701是一种可溶性、重组或基因工程的融合蛋白,旨在纠正ENPP1和ABCC6缺陷引起的矿化途径的缺陷。

Industry: Biotechnology & Medical Research (NEC)

321 Summer Street
Suite 400
BOSTON
MASSACHUSETTS 02210
US

收入报表

  • Annual
  • Quarterly

人们也观看

Natural Gas

2.53 Price
+1.180% 1D Chg, %
多头隔夜费 -0.1001%
空头隔夜费 0.0692%
隔夜费时间 22:00 (UTC)
价差 0.006

BTC/USD

23,559.70 Price
+0.430% 1D Chg, %
多头隔夜费 -0.0500%
空头隔夜费 0.0140%
隔夜费时间 22:00 (UTC)
价差 60.00

US100

12,664.00 Price
+0.140% 1D Chg, %
多头隔夜费 -0.0180%
空头隔夜费 0.0070%
隔夜费时间 22:00 (UTC)
价差 1.8

XRP/USD

0.41 Price
+0.420% 1D Chg, %
多头隔夜费 -0.0500%
空头隔夜费 0.0140%
隔夜费时间 22:00 (UTC)
价差 0.00326

还在找一位您可以信任的经纪商吗?

加入成为全球485,000万多名交易者的一份子,选择利用Capital.com进行交易吧。

1. 创建和验证您的账户 2. 进行存款 3. 找到适合您的交易